OTLC

Oncotelic therapeutics inc

0.00 USD
0.00 (0.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Oncotelic therapeutics inc stock is down -100% since 30 days ago. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 41.94% of the previous 30 May’s closed higher than April.

About Oncotelic therapeutics inc

Oncotelic Therapeutics, Inc. engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma. It also develops OXi4503 for the. treatment of acute myeloid leukemia and myelodysplastic syndromes.